Research Center in Infectious Diseases, CHU of Quebec and Laval University, Quebec City, Quebec, Canada.
Research Center in Infectious Diseases, CHU of Quebec and Laval University, Quebec City, Quebec, Canada
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01044-17. Print 2017 Nov.
Letermovir is an investigational antiviral agent with a novel mechanism of action involving the viral terminase (pUL56). We evaluated the impact of the V236M mutation in the gene alone and in combination with the E756K mutation in the gene on drug susceptibility and viral replicative capacity of recombinant human cytomegalovirus. The double mutant exhibited at least borderline resistance to all antivirals tested (ganciclovir, foscarnet, cidofovir, brincidofovir, and letermovir) and replicated less efficiently than the wild-type virus .
洛韦莫韦是一种具有新型作用机制的抗病毒药物，该机制涉及病毒末端酶（pUL56）。我们评估了 基因中的 V236M 突变单独存在和与 基因中的 E756K 突变共同存在对重组人巨细胞病毒药物敏感性和病毒复制能力的影响。双突变体对所有测试的抗病毒药物（更昔洛韦、膦甲酸钠、西多福韦、布西福韦和洛韦莫韦）至少表现出边缘耐药性，并且复制效率低于野生型病毒。
